Search Results
Jun 16, 2026, 09:13 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in Badger Meter, Inc. Lawsuit - BMI
June 16, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Badger Meter, Inc. (NYSE: BMI).
More news about: The Gross Law Firm
Jun 16, 2026, 05:24 ET BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Badger Meter, Inc. (NYSE: BMI) between April 18, 2024 and April 16, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead
More news about: THE ROSEN LAW FIRM, P. A.
Jun 15, 2026, 22:16 ET Robbins LLP Urges BMI Stockholders Who Lost Money Investing in Badger Meter, Inc. to Contact the Firm for Information About Leading the Class Action
LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Badger Meter, Inc. (NYSE: BMI) common stock between April 18, 2024 and April 16, 2026. Badger Meter manufactures and sells water measurement and management products.
More news about: Robbins LLP
Jun 15, 2026, 16:10 ET Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
using the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) and PWS-related behaviors were assessed using the PWS Profile questionnaire (PWSP). BMI and long-term safety were also assessed. Study results included:Participants who restarted VYKAT XR after placebo during the
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 15:28 ET Badger Meter, Inc. (BMI) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
BMI) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Jun 15, 2026, 08:30 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
YearsCardiometabolic clinical outcomes were evaluated through up to two years of CRENESSITY treatment, including changes in body weight, body mass index (BMI), body composition and insulin resistance, as assessed by the homeostatic model assessment for insulin resistance (HOMA‑IR) at Months 12 and 24. To avoid
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 03:54 ET BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit with the Schall Law Firm
BMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Jun 12, 2026, 08:00 ET Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
safety of bofanglutide injection in adult participants who had inadequate weight control despite lifestyle interventions and had either a BMI > 30 kg/m², or a BMI ≥ 27 kg/m² accompanied by weight-related comorbidities (excluding type 2 diabetes). Participants were randomized to receive bofanglutide
More news about: Gan & Lee Pharmaceuticals
Jun 12, 2026, 06:02 ET 12 Press Releases You Need to See This Week
complicationsIn TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity.
More news about: PR Newswire
Jun 11, 2026, 19:05 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Badger Meter, Inc. of Class Action Lawsuit and Upcoming Deadlines - BMI
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-badger-meter-inc-of-class-action-lawsuit-and-upcoming-deadlines--bmi-302798581.htmlSOURCE
More news about: Pomerantz LLP
Jun 11, 2026, 12:00 ET BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit with the Schall Law Firm
BMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Jun 11, 2026, 09:00 ET BMI Shareholder Alert: Badger Meter, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
70 professionals. Hundreds of millions recovered.Frequently Asked Questions About the BMI LawsuitQ: Who is eligible to join the BMI investor lawsuit? A: Investors who purchased BMI stock or securities between April 18, 2024 and April 16, 2026 and suffered financial losses may
More news about: SueWallSt.com
Jun 10, 2026, 17:00 ET BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Badger Meter, Inc. (NYSE: BMI) between April 18, 2024 and April 16, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead
More news about: THE ROSEN LAW FIRM, P. A.
Jun 10, 2026, 09:00 ET BMI DEADLINE: Levi & Korsinsky Reminds Badger Meter, Inc. Investors of Upcoming Securities Class Action Deadline
consecutive years). Over 70 professionals. Hundreds of millions recovered.Frequently Asked Questions About the BMI LawsuitQ: Who are the defendants named in the BMI lawsuit? A: The complaint names Badger Meter, Inc. and individual defendants including CEO Kenneth C. Bockhorst,
More news about: Levi & Korsinsky, LLP
Jun 10, 2026, 02:20 ET Acer Listed on 2026 Dow Jones Best-in-Class World Index
through the Corporate Sustainability Assessment (CSA). It represents the top 10% of the largest 2,500 companies in the S&P Global Broad Market Index (BMI) based on long-term economic, environmental, and social criteria. The S&P Global Sustainability Yearbook covers more than 9,200 companies worldwide,
More news about: Acer
Jun 09, 2026, 09:00 ET BMI Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Badger Meter, Inc. Securities Lawsuit - Contact The Gross Law Firm
June 9, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Badger Meter, Inc. (NYSE: BMI).
More news about: The Gross Law Firm
Jun 08, 2026, 16:15 ET Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results
OverweightThe phase 2b VISTA trial evaluated the efficacy, safety, and tolerability of elecoglipron in adults with obesity (body mass index (BMI) ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. Over 36 weeks, the randomized, placebo-controlled study included 310 adults
More news about: American Diabetes Association
Jun 08, 2026, 14:30 ET ACHIEVE Trials Demonstrate Comparative Benefits of Novel, Small-Molecule Oral GLP-1 RA, Expanding Oral Treatment Options for Patient Population in Need of Alternative Solutions
diabetes inadequately controlled by insulin glargine. Among 546 randomized participants (median age 61 years, 52.9% male), the mean A1C was 8.5%, and BMI was 30.8. Up to about 70% of participants receiving orforglipron achieved A1C below 7% (a common target for blood glucose control), compared with about
More news about: American Diabetes Association
Jun 08, 2026, 14:30 ET Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
Foundayo is superior in A1C reduction from baseline after 40 weeks, compared to placebo. Study participants had an A1C between ≥7.0% and ≤10.5% and a BMI of ≥23 kg/m2.All participants in the Foundayo treatment arms started the study at a dose of Foundayo 0.8 mg once-daily and then increased
More news about: Eli Lilly and Company
Jun 08, 2026, 09:14 ET BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit with the Schall Law Firm
national shareholder rights litigation firm, reminds investors of a class action lawsuit against Badger Meter, Inc. ("Badger" or "the Company") (NYSE: BMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Jun 08, 2026, 08:31 ET MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
progressive weight loss up to 9.1% at the 48 mg dose level without evidence of plateau, along with consistent reductions in waist circumference and BMI in a once-weekly regimen without titration. Importantly, the data also demonstrates a sustained and progressive metabolic effect through Day 54, supporting
More news about: MetaVia Inc.
Jun 08, 2026, 04:30 ET 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
eligible participants with/without overweight or obesity (BMI 20–40 kg/m²) to receive once-daily single doses of IBI3032 at 0.3 mg, 1.0 mg, 3.0 mg and 6.0 mg. The multiple-ascending dose (MAD) study recruited a total of 79 overweight/obese participants (BMI 24–40 kg/m²) to receive once-daily oral IBI3032 for
More news about: Innovent Biologics
Jun 07, 2026, 20:10 ET Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
were 5.4%, 7.0%, and 7.7% for the 20 mg, 40 mg, and 60 mg maintenance doses, respectively. Mean baseline body weight was 107.3 kg, and body mass index (BMI) was 38.6 kg/m². From a safety perspective, ASC30 titrated weekly to the target dose demonstrated approximately one-half the rate of vomiting observed
More news about: Ascletis Pharma Inc.
Jun 07, 2026, 14:30 ET Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
Loss in Adults Living with MASLD/MASH and Obesity The SYNCHRONIZE-MASLD trial enrolled adults with excess weight or obesity (BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² with at least one weight-related health condition) who also have MASLD/MASH, serious fatty liver diseases. Participants
More news about: American Diabetes Association
Jun 07, 2026, 14:30 ET Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
vs. Semaglutide, ≥10% Weight Loss Response Rate Nearly Twofold HigherThis study enrolled 163 adult patients with obesity (body mass index [BMI]≥30 kg/m²) across 17 research centers in China. Participants were randomized 1:1 to receive once-weekly subcutaneous injections of either ecnoglutide
More news about: Sciwind Biosciences Co., Ltd.